New drug promises relief for inflammatory pain

August 27, 2014

Pain from inflammation sidelines thousands of Americans each year. Many face a tough choice: deal with the pain, take a potentially addictive opioid or use a nonsteroidal anti-inflammatory drug that may increase risk for cardiovascular disease or gastrointestinal bleeding.

Now, researchers at the Stanford University School of Medicine have discovered a compound thought to be nonaddictive and safe for the heart and gastrointestinal system that reduces in and rats. They call the compound Alda-1.

"Finding a new pain medication is important because we need a safer drug; there are 17,000 deaths from prescription opiate overdoses a year alone," said Daria Mochly-Rosen, professor of chemical and systems biology.

A paper describing the researchers' findings will be published Aug. 27 in Science Translational Medicine. Mochly-Rosen is senior author of the paper, and former Stanford postdoctoral scholars Vanessa Zambelli, PhD, and Eric Gross, MD, PhD, are the lead authors.

The researchers have been working with Alda-1 for more than five years. They discovered it while searching for the reason that moderate drinkers have less-severe heart attacks than nondrinkers or heavy alcohol drinkers. They found that alcohol increases the activity of an enzyme called 2. This enzyme breaks down a byproduct of alcohol called acetaldehyde, forming free radicals that can damage cells. The enzyme also breaks down additional toxic aldehydes that are formed in the body because of oxidative stress, such as that occurring during a heart attack. Alda-1, an abbreviation for aldehyde dehydrogenase activator 1, kicks the enzyme into high gear, allowing it to break down toxic aldehydes more quickly and leaving less time for them to cause damage. (Coincidentally, Alda is also the name of Mochly-Rosen's 87-year-old mother.)

Now, Alda-1 has shown its prowess as a painkiller.

Mochly-Rosen and her team knew that inflammation causes toxic aldehyde accumulation. But no one had asked whether the enzyme aldehyde dehydrogenase 2, which breaks down these aldehydes, regulates inflammatory pain.

"We made what may appear as a crazy leap," Mochly-Rosen said.

The researchers conducted a series of experiments to illuminate the enzyme's role in the perception of inflammatory pain. First, they demonstrated that mice and rats with an inflamed paw felt less pain when they received Alda-1. Yet the underlying condition, the inflammation, remained unchanged after Alda-1 treatment.

Then, Che-Hong Chen, PhD, a senior research scientist and co-author of the paper, bioengineered a mouse with a mutation in aldehyde dehydrogenase 2 that mimics a mutation found in more than a third of Han Chinese, a group that makes up 8 percent of the world population. In humans, this mutation causes flushing after alcohol consumption because of excess acetaldehyde accumulation.

In mice, the mutation increased sensitivity to inflammatory pain. The researchers then demonstrated increased pain response by injecting the mutant mice with aldehydes and comparing their reactions to those of normal mice. The mice with the mutated enzyme licked and flicked their paws longer than normal mice. When treated with Alda-1, both groups of mice appeared to feel less pain.

Mochly-Rosen said her team plans to investigate whether humans with the mutated enzyme are also more sensitive to pain.

She said the findings demonstrate the importance of basic research.

"I'm not a pain expert, and pain was never a research focus of my lab," Mochly-Rosen said. "We focused our research on this for a completely different reason, and because we are in academia, we could follow a serendipitous finding and develop a new research interest. Hopefully, this finding will translate into helping people who have inflammatory ."

Gross is now an instructor of anesthesiology, perioperative and at Stanford. Researchers at the Butantan Institute in Brazil also contributed to the study.

Explore further: Continuous use of nitroglycerin increases severity of heart attacks, study shows

More information: "Aldehyde dehydrogenase-2 regulates nociception in rodent models of acute inflammatory pain," by V.O. Zambelli et al. stm.sciencemag.org/lookup/doi/ … scitranslmed.3009539

Related Stories

Continuous use of nitroglycerin increases severity of heart attacks, study shows

November 2, 2011
When given for hours as a continuous dose, the heart medication nitroglycerin backfires -- increasing the severity of subsequent heart attacks, according to a study of the compound in rats by researchers at the Stanford University ...

Genotyping of Aldehyde dehydrogenase2 (ALDH2) solves the mystery of Fanconi anemia

January 20, 2014
Kyoto University research group led by Prof. Minoru Takata has found the deleterious impact of the ALDH2 variant genotype in human Fanconi anemia (FA) patients. This finding strongly suggests the important role of endogenous ...

Avoiding that new year's hangover

December 31, 2013
(HealthDay)—Hangover headaches are a common problem over the holidays, but there are ways to prevent them, an expert says.

Recommended for you

Targeting 'broken' metabolism in immune cells reduces inflammatory disease

July 12, 2017
The team, led by researchers at Imperial College London, Queen Mary University of London and Ergon Pharmaceuticals, believes the approach could offer new hope in the treatment of inflammatory conditions like arthritis, autoimmune ...

A perturbed skin microbiome can be 'contagious' and promote inflammation, study finds

June 29, 2017
Even in healthy individuals, the skin plays host to a menagerie of bacteria, fungi and viruses. Growing scientific evidence suggests that this lively community, collectively known as the skin microbiome, serves an important ...

Inflammatory bowel disease: Scientists zoom in on genetic culprits

June 28, 2017
Scientists have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease. The team from the Wellcome Trust Sanger Institute and their collaborators ...

Trials show unique stem cells a potential asthma treatment

June 28, 2017
A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

Researchers find piece in inflammatory disease puzzle

May 23, 2017
Inflammation is the process by which the body responds to injury or infection but when this process becomes out of control it can cause disease. Monash Biomedicine Discovery Institute (BDI) researchers, in collaboration with ...

Researchers reveal potential target for the treatment of skin inflammation in eczema and psoriasis

May 22, 2017
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep. Atopic dermatitis, also known as eczema, is primarily driven by an allergic reaction, while psoriasis is considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.